MicroRNAs as biomarkers in pituitary tumors. 2014

Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
‡Division of Neurosurgery, Department of Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; §Department of Laboratory Medicine, Division of Pathology, and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada; ¶Division of Cardiology, Magna Graecia University, Catanzaro, Italy; ‖Department of Pathology, Acıbadem University, School of Medicine, Maltepe, Istanbul, Turkey.

The use of extracellular microRNAs (miRNAs) as circulating biomarkers is currently leading to relevant advances in the diagnosis and assessment of prognosis of several diseases. Specific miRNAs have also been shown to play a role in the pathophysiology of many neoplastic and non-neoplastic diseases. A number of studies have demonstrated that miRNAs show differential expression in various tumors, such as in the prostate, ovary, lung, breast, brain, and pituitary. Recent findings have built connections between miRNAs that are deregulated within the tumor and their presence in peripheral blood. MiRNAs have been shown to be stable in the blood where they are present in either free and/or uncomplexed form, as well as packed in microvesicles, exosomes, and apoptotic bodies, or bound to different proteins. Because the pituitary is a highly vascularized organ that releases hormones into the circulation, miRNAs would be useful biomarkers for the diagnosis of pituitary tumors, as well as for predicting or detecting recurrence after surgery. Here we review the biological significance of miRNAs in pituitary tumors and the potential value of circulating miRNAs as biomarkers.

UI MeSH Term Description Entries
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D035683 MicroRNAs Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing. RNA, Small Temporal,Small Temporal RNA,miRNA,stRNA,Micro RNA,MicroRNA,Primary MicroRNA,Primary miRNA,miRNAs,pre-miRNA,pri-miRNA,MicroRNA, Primary,RNA, Micro,Temporal RNA, Small,miRNA, Primary,pre miRNA,pri miRNA

Related Publications

Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
September 2021, Non-coding RNA,
Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
November 2017, Molecular and cellular endocrinology,
Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
August 2019, The Urologic clinics of North America,
Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
February 2013, Cancer letters,
Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
May 2018, Clinical chemistry and laboratory medicine,
Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
January 2015, Experientia supplementum (2012),
Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
January 2013, Critical reviews in oncogenesis,
Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
January 2014, Stem cell investigation,
Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
January 2013, Diagnostics (Basel, Switzerland),
Antonio Di Ieva, and Henriett Butz, and Marzia Niamah, and Fabio Rotondo, and Salvatore De Rosa, and Aydin Sav, and George M Yousef, and Kalman Kovacs, and Michael D Cusimano
January 2015, Frontiers in genetics,
Copied contents to your clipboard!